Enlivex Ltd. ENLV
Enlivex Ltd. (Nasdaq: ENLV) is an immunology/inflammation drug developer. Its lead program, Allocetra, is in Phase 2 for Moderate-to-severe age-related primary knee osteoarthritis. Its next catalyst on record is Allocetra: Enlivex expects topline data from Phase IIb trial of Allocetra in knee osteoarthritis by the end of the second quarter of 2027. (Q2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Allocetra — Enlivex expects topline data from Phase IIb trial of Allocetra in knee osteoarthritis by the end of the second quarter of 2027. (Q2 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Allocetra (intra-articular, Phase IIb) | Age-related primary knee osteoarthritis | biologic-other | Phase 2 |
Recent results and decisions
- Nov 2, 2026positive Allocetra™ Phase IIa trial reports positive 12-month topline data with 79.2% responders in patients aged 64+ versus 47.6% placebo.
At 12 months: 79.2% responders in the Allocetra™ group vs. 47.6% in the placebo group (p=0.027)
Filing - Oct 28, 2026completed enrollment Enlivex announces that 135 out of a total planned 182 patients have been randomized and administered the first injection of Allocetra in its Phase 2b trial for knee osteoarthritis.
135 patients, out of a total planned 182, have been randomized and were administered the first injection of AllocetraTM; enrollment actively ongoing at clinical sites in the United States and in Europe
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.